Disclosed is the use of a Raf inhibitor e.g. 1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl} -(4-trifluoromethylphenyl)-amine for the preparation of a medicament for the treatment of papillary thyroid cancer, wherein the Raf inhibitor is a compound of the formula (III) wherein each R1 is independently selected from alkyl, alkoxy, hydroxy, halo, (alkyl)sulfanyl, (alkyl)sulfonyl, cycloalkyl, heterocycloalkyl, phenyl and heteroaryl each R4 is independently selected from hydroxy, alkyl, alkoxy, halo, carboxyl, alkoxy)carbonyl, aminocarbonyl, carbonitrile, cycloalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, phenyl and heteroaryl a is 1, 2, 3, 4 or 5 and c is 1 or 2 or a tautomer, stereoisomer, polymorph, or ester, thereof or a pharmaceutically acceptable salt of the compound, tautomer, stereoisomer, polymorph, or ester thereof.
